For patients with RA, biological DMARDs (tumor necrosis factor inhibitors, IL‐1 inhibitors, IL‐6 receptor inhibitors, and CD20 blockers) are used to manage atherosclerotic CVD risk and prevent atherosclerosis from forming.5, 26. This evidence concerns the gene TNF and rheumatoid arthritis.